KRAS and intrahepatic cholangiocarcinoma: On the other hand, ICC has lower mutation rates of TP53, SMAD4, APC, and ERBB2 and significantly less frequent mutations in KRAS, CDKN2A, and BRCA1 than in extrahepatic cholangiocarcinoma.